Novo Nordisk A/SNVO
NYSE • Healthcare
$47.08
P/E
1.72
PEG
0.03
FCF Yield
—
Rev Growth YoY
+24.0% YoY
Gross Margin
86.0%
Health Score
7/10
D/E Ratio
0.67
Confidence
LOW
Business Snapshot
Novo Nordisk is a global healthcare leader specialising in diabetes care, obesity treatment, and other chronic metabolic disorders, with its market-leading GLP-1 therapies (Ozempic, Wegovy, Rybelsus) driving the vast majority of revenue. The company operates in the large and rapidly expanding metabolic disease market, where it holds a dominant position as the clear market leader in both diabetes and weight management. While the market capitalisation is not available in the provided data, the company generates substantial financial scale with TTM revenue of $327.80 billion and net income of $121.96 billion. The defining characteristic that sets Novo Nordisk apart is its entrenched portfolio of GLP-1 receptor agonists, protected by a combination of patent barriers, manufacturing complexity, and first-mover advantage in a market with rapidly growing demand.
Financial Health
Gross margin stands at a robust 86.0%, improving from 80.9% in the prior year, while the TTM net margin of 37.2% reflects strong operating leverage and pricing power. The balance sheet is in solid shape with a manageable debt-to-equity ratio of 0.67x, though the current ratio of 0.8x indicates the company has slightly less current assets than current liabilities, which warrants monitoring for short-term liquidity pressure...
Risk Assessment
- VALUATION — P/E of 1.72x is below the sector average of 22x, but Price/Book of 7.44x and EV/EBITDA of 46.5x indicate elevated asset and enterprise value multiples.
- EARNINGS QUALITY — Only 2 of the last 4 quarters beat analyst estimates, suggesting management guidance has limited predictive reliability.
- DEBT / LIQUIDITY — Current ratio of 0.8x falls below the 1.0x threshold, indicating the company holds fewer current assets than current liabilities.
- 52-WEEK POSITION — The current price of $47.08 sits below the midpoint of the 52-week range and is 42.2% below the 52-week high of $81.44.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed.
- VALUATION DIVERGENCE — FMP DCF fair value of $98.06 suggests deep undervaluation, but the Python DCF could not be calculated due to data inconsistencies, creating uncertainty around intrinsic value....
Metric deep-dives